Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced shipment restrictions following patient deaths before being partially reinstated.

Sarepta Therapeutics (SRPT) surpasses Q2 2025 estimates with strong ELEVIDYS sales and Roche milestone payments, driving revenue growth and investor optimism.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics.

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures rose 0.1%.